News & Updates
Filter by Specialty:
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022
byNatalia Reoutova
A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022ADHD more likely in preschoolers with lazy eye; impaired fine motor skill a mediator
08 May 2022
Amblyopic children are at an increased risk of attention-deficit/hyperactivity disorder (ADHD), reports a recent Korea study. Deficits in the development of fine motor skills may contribute to such a correlation.
ADHD more likely in preschoolers with lazy eye; impaired fine motor skill a mediator
08 May 2022Platelet function a potential biomarker of Alzheimer’s disease
07 May 2022
A higher platelet response in middle-aged individuals who are free of antiplatelet therapy carries an increased risk of dementia in late life, according to a cohort study with 20 years of follow up.